ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004
Retrieved on:
Tuesday, January 18, 2022
Atopic dermatitis, JAAD, IPC, Patient, Harvard University, PARK, Dean (education), Clinical trial, University of Colorado Denver School of Public Affairs, Inflammation, KOL, Self-signed certificate, Harvard Medical School, Psoriatic arthritis, Safety, ASLN, Assessment, American Academy, GLOBE, University of California, Davis, AD, University, Leadership, Public health, Nasdaq, Harvard T.H. Chan School of Public Health, IEC, JAMA Dermatology, Doctor of Philosophy, MD, USC, Harvard School of Dental Medicine, National Psoriasis Foundation, Trial of the century, Skin, Journal of the American Academy of Dermatology, Pharmaceutical industry, Medical device, Research, Psoriasis, Dermatology
MENLO PARK, Calif., and SINGAPORE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host the second episode in its series of Key Opinion Leader (KOL) events on the emerging Atopic Dermatitis (AD) landscape and ASLAN004, on Thursday, January 20, 2022, at 12:00pm ET.
Key Points:
- Dr April Armstrong, MD MPH, will be the second KOL to speak at ASLANs A4 webinar series: Aspects of Atopic Dermatitis and ASLAN004.
- Dr Armstrong has conducted over 150 clinical trials and has significant expertise in inflammatory skin diseases, with a specialty in AD.
- ASLANs A4 webinar series: Aspects of Atopic Dermatitis and ASLAN004 features Dialogues with International Thought Leaders in Dermatology, a series of Key Opinion Leader (KOL) events on the emerging Atopic Dermatitis (AD) landscape and ASLAN004.
- The first episode of the series in October 2021 featured Dr Jonathan Silverberg MD PhD MPH, who discussed Heterogeneity of Atopic Dermatitis.